Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Weight Loss 1Neoplasms 1Fatigue 1Anorexia 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
EOM613 × Clear all
NCT00765466 2019-03-14

A Phase II Open Label, Multi-Center Study With AVR118 in Anorectic Patients With Recurrent or Advanced Malignancies

McGill University

Phase 2 Terminated
30 enrolled
Tumor-Agnostic

Neoplasms

NCT01206335 2012-11-27

Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia

Ohr Pharmaceutical Inc.

Phase 2 Unknown
20 enrolled

Anorexia, Fatigue, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡